Page last updated: 2024-09-03

cp 115953 and etoposide

cp 115953 has been researched along with etoposide in 11 studies

Compound Research Comparison

Studies
(cp 115953)
Trials
(cp 115953)
Recent Studies (post-2010)
(cp 115953)
Studies
(etoposide)
Trials
(etoposide)
Recent Studies (post-2010) (etoposide)
200018,3063,6934,900

Protein Interaction Comparison

ProteinTaxonomycp 115953 (IC50)etoposide (IC50)
nuclear receptor coactivator 1 isoform 1 [Homo sapiens]Homo sapiens (human)1.153
nuclear receptor coactivator 3 isoform aHomo sapiens (human)1.4284
Polyunsaturated fatty acid lipoxygenase ALOX15Oryctolagus cuniculus (rabbit)3.187
Caspase-3Homo sapiens (human)1
DNA topoisomerase 2-betaHomo sapiens (human)0.4299
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)4.18

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's10 (90.91)18.2507
2000's1 (9.09)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aldous, SC; Coughlin, SA; Dorff, PH; Gruett, MD; Lesher, GY; Rake, JB; Reuman, M; Singh, B; Wentland, MP1
Gootz, TD; Martin, BA; McGuirk, PR; Moynihan, M; Osheroff, N; Robinson, MJ; Sutcliffe, JA1
Chung, IK; Gootz, TD; McGuirk, PR; Muller, MT; Spitzner, JR1
Elsea, SH; Hsiung, Y; Nitiss, JL; Osheroff, N1
Forsgren, A; Riesbeck, K1
Corbett, AH; Elsea, SH; Osheroff, N; Westergaard, M1
Corbett, AH; Osheroff, N; Robinson, MJ1
Corbett, AH; Hong, D; Osheroff, N1
Burden, DA; Elsea, SH; Lomenick, JP; Osheroff, N; Westergaard, M1
Anderson, VE; Gootz, TD; Kaczmarek, FS; Osheroff, N; Zaniewski, RP1
Bromberg, KD; Burgin, AB; Osheroff, N1

Reviews

1 review(s) available for cp 115953 and etoposide

ArticleYear
Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes.
    Cancer chemotherapy and pharmacology, 1994, Volume: 34 Suppl

    Topics: Amsacrine; Animals; Anti-Infective Agents; Antineoplastic Agents; DNA; DNA Damage; DNA Topoisomerases, Type II; Etoposide; Fluoroquinolones; Genistein; Humans; Isoflavones; Models, Structural; Quinolones; Topoisomerase II Inhibitors

1994

Other Studies

10 other study(ies) available for cp 115953 and etoposide

ArticleYear
Mammalian topoisomerase II inhibitory activity of 1-cyclopropyl-6,8- difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarb oxylic acid and related derivatives.
    Journal of medicinal chemistry, 1993, Sep-17, Volume: 36, Issue:19

    Topics: Animals; Anti-Infective Agents; Fluoroquinolones; HeLa Cells; Humans; Leukemia P388; Mice; Quinolones; Structure-Activity Relationship; Topoisomerase II Inhibitors

1993
Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage.
    The Journal of biological chemistry, 1991, Aug-05, Volume: 266, Issue:22

    Topics: Animals; Anti-Infective Agents; Catalysis; Cell Line; Cell Survival; Cricetinae; Cricetulus; DNA; DNA Topoisomerases, Type II; Drosophila melanogaster; Electrophoresis, Agar Gel; Etoposide; Fluoroquinolones; Hydrolysis; Molecular Structure; Quinolones

1991
Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
    Molecular pharmacology, 1995, Volume: 48, Issue:2

    Topics: Amsacrine; Anti-Infective Agents; Base Sequence; DNA; DNA Topoisomerases, Type II; Etoposide; Fluoroquinolones; Humans; Hydrolysis; Molecular Sequence Data; Quinolones; Teniposide; Topoisomerase II Inhibitors

1995
A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors.
    The Journal of biological chemistry, 1995, Sep-01, Volume: 270, Issue:35

    Topics: Anti-Infective Agents; Base Sequence; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Escherichia coli; Etoposide; Fluoroquinolones; Genes, Bacterial; Genes, Fungal; Kinetics; Macromolecular Substances; Molecular Sequence Data; Mutagenesis, Site-Directed; Oligodeoxyribonucleotides; Point Mutation; Quinolones; Recombinant Proteins; Saccharomyces cerevisiae; Serine; Species Specificity; Tryptophan

1995
CP-115,953 stimulates cytokine production by lymphocytes.
    Antimicrobial agents and chemotherapy, 1995, Volume: 39, Issue:2

    Topics: Anti-Infective Agents; Cells, Cultured; Cytokines; DNA Damage; Etoposide; Fluoroquinolones; Humans; Interferon-gamma; Interleukin-2; Lymphocyte Activation; Novobiocin; Quinolones; RNA, Messenger; T-Lymphocytes; Thymidine; Topoisomerase II Inhibitors

1995
Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.
    Biochemistry, 1993, Apr-13, Volume: 32, Issue:14

    Topics: Adenosine Triphosphate; Amsacrine; Animals; Anti-Infective Agents; Antineoplastic Agents; Binding Sites; Cell Nucleus; DNA Topoisomerases, Type II; DNA, Bacterial; Drosophila melanogaster; Escherichia coli; Etoposide; Fluoroquinolones; Genistein; Hydrolysis; Isoflavones; Novobiocin; Plasmids; Quercetin; Quinolones; Topoisomerase II Inhibitors

1993
Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme.
    The Journal of biological chemistry, 1993, Jul-05, Volume: 268, Issue:19

    Topics: Amsacrine; Animals; Anti-Infective Agents; Binding Sites; Cell Line; Cell Nucleus; DNA; DNA Topoisomerases, Type II; DNA, Superhelical; Drosophila melanogaster; Drug Interactions; Etoposide; Fluoroquinolones; Genistein; Growth Inhibitors; Isoflavones; Kinetics; Novobiocin; Protein Binding; Quinolones; Structure-Activity Relationship; Topoisomerase II Inhibitors

1993
Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
    Biochemistry, 1997, Mar-11, Volume: 36, Issue:10

    Topics: Amsacrine; Animals; Anti-Infective Agents; Antineoplastic Agents; Binding Sites; CHO Cells; Ciprofloxacin; Cricetinae; DNA Topoisomerases, Type II; DNA, Superhelical; Drosophila melanogaster; Electrophoresis, Agar Gel; Enzyme Activation; Etoposide; Fluoroquinolones; Genistein; Isoflavones; Kinetics; Molecular Structure; Quinolones

1997
Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries.
    The Journal of biological chemistry, 1999, Dec-10, Volume: 274, Issue:50

    Topics: Anti-Infective Agents; Biological Evolution; Ciprofloxacin; DNA Damage; DNA Repair; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Escherichia coli; Etoposide; Fluoroquinolones; Gram-Positive Bacteria; Kinetics; Quinolones; Staphylococcus aureus

1999
Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage.
    Biochemistry, 2003, Apr-01, Volume: 42, Issue:12

    Topics: Amino Acid Substitution; Anti-Infective Agents; Antigens, Neoplasm; Antineoplastic Agents; Base Sequence; Binding Sites; Catalytic Domain; DNA; DNA Damage; DNA Repair; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Activation; Etoposide; Fluoroquinolones; Humans; In Vitro Techniques; Kinetics; Models, Biological; Oligodeoxyribonucleotides; Recombinant Proteins; Substrate Specificity

2003